Mylan Gets First-Ever GMP Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s GMP warning letter to Mylan cites failure to complete a required content uniformity test for generic Imodium manufactured at Puerto Rico plant.